Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC58H69N7O15 |
InChIKeyGEZKTBXHVGULHM-LKHQGNJTSA-N |
CAS Registry- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 21 Feb 2020 | |
| Neoplasms | Preclinical | Germany | 21 Feb 2020 |





